AstraZeneca (NASDAQ:AZN) announced Thursday that its monoclonal antibody sipavibart reached primary goals as a treatment for COVID-19 prevention in a Phase 3 trial for immunologically weaker individuals.

The company said its global trial, SUPERNOVA, for individuals aged 12 and above with immunocompromising conditions such as blood cancer and kidney conditions, achieved dual primary endpoints.

SUPERNOVA was designed to evaluate sipavibart against two comparators, tixagevimab/cilgavimab, a monoclonal antibody AstraZeneca (AZN) had previously marketed as Evusheld for COVID prevention and placebo.

As for its first primary endpoint, sipavibart, formerly known as AZD3152, outperformed comparators with a statistically significant effect on reducing the risk of symptomatic COVID-19.

The company said that the investigational medicine also reduced infections caused by SARS-CoV-2 variants not containing the F456L mutation, reaching SUPERNOVA’s second primary endpoint.

The Anglo-Swedish drugmaker is currently engaged in discussions to seek regulatory clearances for sipavibart.

More on AstraZeneca

• AstraZeneca: A Triple Shot Of Income, Growth, And Value
• AstraZeneca: Strong In A Weak Market
• AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript
• AstraZeneca, Pfizer to invest combined $900M+ in France for R&D, production
• AstraZeneca is withdrawing COVID shot worldwide due to vaccine glut